To read the full story, subscribe or sign in.

Symphogen, Genentech Sign Antibodies Deal Worth $330M

June 11, 2008

In its first major deal, Danish biotech Symphogen AS agreed to a $330 million collaboration with Genentech Inc. to discover and develop antibody therapeutics against three undisclosed infectious disease targets.(BioWorld Today)

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for July 22, 2025.

Coinfections and diversity paint the many shades of HIV cure

BioWorld

We all look different to HIV, a virus that destroys the immune system. The defensive cells record every interaction with foreign agents, infections from viruses...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 22, 2025.

Livzon’s IL-17A/F meets phase III endpoints in plaque psoriasis

BioWorld

Livzon Mabpharm Inc.’s anti-IL-17A/F monoclonal antibody, LZM-012, met the primary endpoint in a phase III trial in moderate to severe plaque psoriasis. Conducted...

Engineered IL-18 variants with improved drug-like properties show promise for cancer immunotherapy

BioWorld Science

Interleukin-18 (IL-18) is a pro-inflammatory cytokine that plays a crucial role in promoting antitumor immunity by activating T and natural killer (NK) cells....